The 3rd edition of the MarketsandMarkets Next Gen Microbiome and Probiotics will be held as a Virtual conference on Thursday 25th February and Friday 26th February 2021.
What is the 3rd Next Gen Microbiome and Probiotics conference and Why attend?
The significant role that the microbiome, probiotics, and prebiotics play in the overall wellbeing is an area that has attracted a lot of research. This conference gives an in-depth view of this field including research, applications related to therapeutics, speculation, and administrative obstacles that are looked at by experts.
The 3rd edition of the Next Gen Microbiome and Probiotics conference is an opportunity that brings together experts from a diversity of fields such as biotech, pharma, academicians, and investors, who will be discussing the most ingenious research together with technological advances. There will also be discussions on the nutraceutical, consumer approaches, and clinical applications, with key sessions on research and development to commercialization.
Who should attend the 3rd Next Gen Microbiome and Probiotics conference?
Medical Directors, Principal Investigators, Methodologists, and other clinical research professionals from pharmaceuticals, nutraceuticals, and therapeutics-based organizations from the departments: Microbiome discovery, Department of Biochemistry and Immunology, Microbiome Science, Microbiology, Biological Science, Gut Biology, Human microbiome, Drug discovery, Therapeutics, and Immunotherapy.
Directors, Heads, Professors/Assistant Professors/ Associate Professor, Research Scholars, Scientists from the departments: Microbiology, Microbiome Therapeutics, Microbiome, Gastroenterology, Immunology, Bioinformatics, Obstetrics, Neonatology, Functional foods, Pediatrics, Nutritionists/dieticians, Gut inflammation, Mucosal immunity, and Immunopharmacology Group.
Agenda for 3rd Next Gen Microbiome and Probiotics conference 2021
Thursday 25th February 2021
Todd Krueger President & CEO of AOBiome – The development of ammonia-oxidizing bacteria to treat pruritus associated with atopic dermatitis in a 576 patient Phase 2b trial
David Kyle Executive Chairman & CSO of Evolve Biosystems – Infant gut microbiome
Kathy Musa-Veloso Senior Director: Nutrition, Health Claims, and Clinical Trials at Intertek – Designing Beauty from Within: Optimizing Clinical Study Protocols in Probiotic Research
Maya Ivanjesku Chief Scientific Officer at Dakota Biotech – Therapeutic advances in creating Next Generation skincare products using Live Probiotic Technology
Linda Krebs Co-Founder & COO of Bebe and Bella and Allison Krebs-Bensch CEO of US Pharmaceutical Corporation- V-Bella Homeopathic Boric Acid and Probiotic blend vaginal suppositories
Naveen Jain Founder & CEO of Viome – Imagine living in a world where Illness is optional – Understanding human biology to prevent and intercept Chronic diseases
Julie Schwedock Associate Director of Microbial Development Team at Takeda Pharmaceuticals – LBPs: What to consider when choosing CDMOs
Friday 26th February 2021
Petronille Houdart Skincare Director at Sequential Skin – Personalised Beauty Prescription
Julius Goepp Founder & CEO of Scaled Microbiomics – Modulating Microbiome Signaling Pathways: A Drug Discovery Platform
Skyler Stein President of Gladskin – Bacteriophage Endolysins as a novel approach to modulate the skin microbiome
Emily Stein CEO of Primal Health Inc. – The Oral Microbiome, Mucosal Inflammation and its Rehabilitation
View past events by MarketsandMarkets